Neutrophil-lymphocyte and platelet-lymphocyte ratios in endometrial hyperplasia

Objective The purpose of present study was to evaluate association between neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) and endometrial hyperplasia (EH). Methods One hundred and ten women with abnormal uterine bleeding were included into the study. Blood samples were drawn from all patients to obtain complete blood cell counts, neutrophil-leukocyte ratio and platelet-leukocyte ratio before endometrial curettage procedure initiated. The patients were divided into three groups due to their pathological results: group 1, patients with EH without atypia (n=40); group 2, patients with EH with atypia (n=15); and group 3, patients with neither hyperplasia nor cancer as control group (n=55). Blood cell counts, NLRs and PLRs were compared among these groups. Results Based on hemoglobin and platelet counts, there was no significant difference among these groups (P>0.05). Leukocyte and neutrophil counts were higher in group 2 (EH with atypia) than group 1 and group 3 (P<0.01). NLR of group 2 was significantly elevated when compared to group 1 and group 3 (P=0.004). PLR was higher in group 1 and group 2 than control group (P=0.024). Conclusion Non-specific inflammatory markers such as NLR and PLR were elevated in women with atypical EH. These markers may be used as a predictor of atypical EH in patients with abnormal uterine bleeding.

[1]  H. Aksoy,et al.  Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding? , 2014, Asian Pacific journal of cancer prevention : APJCP.

[2]  S. Deivendran,et al.  The role of inflammation in cervical cancer. , 2014, Advances in experimental medicine and biology.

[3]  J. Trovik,et al.  Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas. , 2013, Gynecologic oncology.

[4]  C. Friedenreich,et al.  Case–control study of inflammatory markers and the risk of endometrial cancer , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[5]  J. Chang-Claude,et al.  Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort--a factor analysis. , 2013, American journal of epidemiology.

[6]  S. Ozalp,et al.  Platelet volume as a parameter for platelet activation in patients with endometrial cancer , 2013, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[7]  Jia-xin Yang,et al.  Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma , 2013, OncoTargets and therapy.

[8]  G. Zararsiz,et al.  Neutrophil–Lymphocyte Ratio as a Predictor of Disease Severity in Ulcerative Colitis , 2013, Journal of clinical laboratory analysis.

[9]  Jia-xin Yang,et al.  Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy. , 2013, Chinese medical journal.

[10]  M. Beckmann,et al.  Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[11]  Jeong-Won Lee,et al.  Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. , 2012, Anticancer research.

[12]  D. Talwar,et al.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. , 2011, European journal of cancer.

[13]  T. Rohan,et al.  A Prospective Study of Inflammation Markers and Endometrial Cancer Risk in Postmenopausal Hormone Nonusers , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[14]  L. Goldsmith,et al.  Body mass index of patients with endometrial hyperplasia: comparison to patients with proliferative endometrium and abnormal bleeding. , 2011, Journal of reproductive medicine.

[15]  F. Clavel-Chapelon,et al.  Obesity, inflammatory markers, and endometrial cancer risk: a prospective case–control study , 2010, Endocrine-related cancer.

[16]  P. Allavena,et al.  The chemokine system in cancer biology and therapy. , 2010, Cytokine & growth factor reviews.

[17]  M. Knöfler,et al.  Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. , 2009, Placenta.

[18]  J. Metindir,et al.  Preoperative hemoglobin and platelet count and poor prognostic factors in patients with endometrial carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[19]  M. Gultekin,et al.  The value of preoperative platelet count in the prediction of cervical involvement and poor prognostic variables in patients with endometrial carcinoma. , 2006, Gynecologic oncology.

[20]  C. Stefanadis,et al.  Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside. , 2006, Cytokine & growth factor reviews.

[21]  R. Ness,et al.  Inflammation and Endometrial Cancer: A Hypothesis , 2005, Cancer Epidemiology Biomarkers & Prevention.

[22]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[23]  L. Salamonsen Tissue injury and repair in the female human reproductive tract. , 2003, Reproduction.

[24]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[25]  A. Zeleniuch‐Jacquotte,et al.  Role of Exogenous and Endogenous Hormones in Endometrial Cancer , 2001, Annals of the New York Academy of Sciences.

[26]  K. Hatch,et al.  Endometrial cancer, obesity, and body fat distribution. , 1991, Cancer research.